Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | HRH2 | P25021 | 9/20 | 0.47 |
| ▸ | HRH1 | P35367 | 9/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3129914 | 0.96 | KCNH2 (0.54) | KCNH2HRH2HRH1HRH3CA12 | |
| SCHEMBL2954489 | 0.95 | KCNH2 (0.51) | KCNH2HRH2HRH1HRH3CA12 | |
| SCHEMBL3128796 | 0.93 | KCNH2 (0.51) | KCNH2HRH2HRH1HRH3CA12 | |
| SCHEMBL5969996 | 0.88 | KCNH2 (0.46) | KCNH2HRH2HRH1HRH3CA12 | |
| SCHEMBL3423966 | 0.88 | SIGMAR1 (0.45) | KCNH2HRH1CA1CA2 | |
| SCHEMBL3126044 | 0.88 | KCNH2 (0.45) | KCNH2HRH3 | |
| SCHEMBL2960580 | 0.86 | KCNH2 (0.56) | KCNH2HRH2HRH1HRH3MEN1 | |
| Azd7009 SCHEMBL31478886 | 0.86 | KCNH2 (0.68) | KCNH2CA12CA1CA2CA9 | |
| Azd7009 SCHEMBL2966851 | 0.86 | KCNH2 (0.68) | KCNH2CA12CA1CA2CA9 | |
| Azd7009 SCHEMBL6002445 | 0.86 | KCNH2 (0.68) | KCNH2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005558-A1 | Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | claimed |
| EP-1235831-B1 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-03-30 | — | — | EP | claimed |
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB | 2003-08-14 | — | — | US | claimed |
| US-6559143-B1 | Class III electrophysiological activity, drugs which prolong the trans-membrane action potential duration and refractoriness, without affecting cardiac conduction | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | claimed |
| US-7772229-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-7648985-B2 | Oxabispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2010-01-19 | — | — | US | disclosed |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB, (SE) | 2009-12-31 | — | — | US | disclosed |
| US-20090270383-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | US | disclosed |
| US-20090005558-A1 | Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| US-7351821-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2008-04-01 | — | — | US | disclosed |
| US-20070117799-A1 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB, SODERTALJE, SWEDEN | 2007-05-24 | — | — | US | disclosed |
| EP-1765832-A1 | NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| US-20050119259-A1 | Synergistic mixture of anticoagulant and antiarrhythmia agents | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | US | disclosed |
| EP-1235831-B1 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-03-30 | — | — | EP | disclosed |
| EP-1513807-A1 | PHARMACEUTICAL COMBINATION | AstraZeneca AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| EP-1503782-A1 | A COMBINATION PRODUCT COMPRISING MELAGATRAN AND AN ANTI-ARRHYTHMIC OXABISPIDENES | AstraZeneca AB (SE) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003101956-A1 | PHARMACEUTICAL COMBINATION | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003092721-A1 | A COMBINATION PRODUCT COMPRISING MELAGATRAN AND AN ANTI-ARRHYTHMIC OXABISPIDENES | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | WO | disclosed |
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB | 2003-08-14 | — | — | US | disclosed |
| US-6559143-B1 | Class III electrophysiological activity, drugs which prolong the trans-membrane action potential duration and refractoriness, without affecting cardiac conduction | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, RYR1 | KCNH2 9/4885HRH2 680/4885HRH1 765/4885 |
| US-20090270383-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | KCNH1, RYR1, CACNA1E | KCNH2 8/4885HRH2 616/4885HRH1 650/4885 |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, SCN1B | KCNH2 11/4885HRH2 1257/4885HRH1 970/4885 |
| US-20070117799-A1 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, RYR1, CACNA1E | KCNH2 12/4885HRH2 556/4885HRH1 591/4885 |
| US-20050119259-A1 | Synergistic mixture of anticoagulant and antiarrhythmia agents | KCNH1, VKORC1, VKORC1L1 | KCNH2 50/4885HRH2 1216/4885HRH1 1771/4885 |
| US-20090005558-A1 | Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias | KCNH1, RYR1, CACNA1E | KCNH2 8/4885HRH2 616/4885HRH1 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.